Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth.

Pearson HB, Li J, Meniel VS, Fennell CM, Waring P, Montgomery KG, Rebello RJ, Macpherson AA, Koushyar S, Furic L, Cullinane C, Clarkson RW, Smalley MJ, Simpson KJ, Phesse TJ, Shepherd PR, Humbert PO, Sansom OJ, Phillips WA.

Cancer Discov. 2018 Mar 26. doi: 10.1158/2159-8290.CD-17-0867. [Epub ahead of print]

PMID:
29581176
2.

Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling.

Berenjeno IM, Piñeiro R, Castillo SD, Pearce W, McGranahan N, Dewhurst SM, Meniel V, Birkbak NJ, Lau E, Sansregret L, Morelli D, Kanu N, Srinivas S, Graupera M, Parker VER, Montgomery KG, Moniz LS, Scudamore CL, Phillips WA, Semple RK, Clarke A, Swanton C, Vanhaesebroeck B.

Nat Commun. 2017 Nov 24;8(1):1773. doi: 10.1038/s41467-017-02002-4.

3.

Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation.

Liu DS, Duong CP, Haupt S, Montgomery KG, House CM, Azar WJ, Pearson HB, Fisher OM, Read M, Guerra GR, Haupt Y, Cullinane C, Wiman KG, Abrahmsen L, Phillips WA, Clemons NJ.

Nat Commun. 2017 Mar 28;8:14844. doi: 10.1038/ncomms14844.

4.

Novel metastatic models of esophageal adenocarcinoma derived from FLO-1 cells highlight the importance of E-cadherin in cancer metastasis.

Liu DS, Hoefnagel SJ, Fisher OM, Krishnadath KK, Montgomery KG, Busuttil RA, Colebatch AJ, Read M, Duong CP, Phillips WA, Clemons NJ.

Oncotarget. 2016 Dec 13;7(50):83342-83358. doi: 10.18632/oncotarget.13391.

5.

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.

Liu DS, Read M, Cullinane C, Azar WJ, Fennell CM, Montgomery KG, Haupt S, Haupt Y, Wiman KG, Duong CP, Clemons NJ, Phillips WA.

Gut. 2015 Oct;64(10):1506-16. doi: 10.1136/gutjnl-2015-309770. Epub 2015 Jul 17.

PMID:
26187504
6.

Heterozygous expression of the oncogenic Pik3ca(H1047R) mutation during murine development results in fatal embryonic and extraembryonic defects.

Hare LM, Schwarz Q, Wiszniak S, Gurung R, Montgomery KG, Mitchell CA, Phillips WA.

Dev Biol. 2015 Aug 1;404(1):14-26. doi: 10.1016/j.ydbio.2015.04.022. Epub 2015 May 7.

7.

Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly.

Kinross KM, Montgomery KG, Mangiafico SP, Hare LM, Kleinschmidt M, Bywater MJ, Poulton IJ, Vrahnas C, Henneicke H, Malaterre J, Waring PM, Cullinane C, Sims NA, McArthur GA, Andrikopoulos S, Phillips WA.

FASEB J. 2015 Apr;29(4):1426-34. doi: 10.1096/fj.14-262782. Epub 2014 Dec 30.

PMID:
25550458
8.

Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice.

Hare LM, Phesse TJ, Waring PM, Montgomery KG, Kinross KM, Mills K, Roh V, Heath JK, Ramsay RG, Ernst M, Phillips WA.

Biochem J. 2014 Mar 1;458(2):251-8. doi: 10.1042/BJ20131412.

PMID:
24320611
9.

Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors.

Tikoo A, Roh V, Montgomery KG, Ivetac I, Waring P, Pelzer R, Hare L, Shackleton M, Humbert P, Phillips WA.

PLoS One. 2012;7(5):e36924. doi: 10.1371/journal.pone.0036924. Epub 2012 May 30.

10.

An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.

Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, Ivetac I, Tikoo A, Saad M, Hare L, Roh V, Mantamadiotis T, Sheppard KE, Ryland GL, Campbell IG, Gorringe KL, Christensen JG, Cullinane C, Hicks RJ, Pearson RB, Johnstone RW, McArthur GA, Phillips WA.

J Clin Invest. 2012 Feb;122(2):553-7. doi: 10.1172/JCI59309. Epub 2012 Jan 3.

11.

Changes in gene expressions elicited by physiological concentrations of genistein on human endometrial cancer cells.

Konstantakopoulos N, Montgomery KG, Chamberlain N, Quinn MA, Baker MS, Rice GE, Georgiou HM, Campbell IG.

Mol Carcinog. 2006 Oct;45(10):752-63.

PMID:
16705744
12.

Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus.

Phillips WA, Russell SE, Ciavarella ML, Choong DY, Montgomery KG, Smith K, Pearson RB, Thomas RJ, Campbell IG.

Int J Cancer. 2006 May 15;118(10):2644-6.

13.

The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women.

Montgomery KG, Chang JH, Gertig DM, Dite GS, McCredie MR, Giles GG, Southey MC, Hopper JL, Campbell IG.

Breast Cancer Res. 2005;7(3):R353-6. Epub 2005 Mar 4.

14.

Mutation of the PIK3CA gene in ovarian and breast cancer.

Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA.

Cancer Res. 2004 Nov 1;64(21):7678-81.

15.

The DNMT3B C-->T promoter polymorphism and risk of breast cancer in a British population: a case-control study.

Montgomery KG, Liu MC, Eccles DM, Campbell IG.

Breast Cancer Res. 2004;6(4):R390-4. Epub 2004 May 19.

16.

The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years.

Montgomery KG, Gertig DM, Baxter SW, Milne RL, Dite GS, McCredie MR, Giles GG, Southey MC, Hopper JL, Campbell IG.

Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1109-11.

Supplemental Content

Loading ...
Support Center